

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 August 2021 (05.08.2021)



(10) International Publication Number
WO 2021/152314 A1

(51) International Patent Classification:

A61K 35/76 (2015.01) G01N 33/48 (2006.01)
C12N 15/86 (2006.01) C12Q 1/66 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/GB2021/050198

(22) International Filing Date:

28 January 2021 (28.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2001203.5	28 January 2020 (28.01.2020)	GB
2001496.5	04 February 2020 (04.02.2020)	GB
2006987.8	12 May 2020 (12.05.2020)	GB

(71) Applicant: **FREELINE THERAPEUTICS LIMITED**

[GB/GB]; Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(72) Inventors: **FOLEY, Jonathan**; c/o Freeline Therapeutics

Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). **SHEHU, Erald**; c/o Freeline Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(74) Agent: **J A KEMP LLP**; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IMPROVED ASSAY FOR DETERMINING NEUTRALISING ANTIBODY TITRE TO A VIRAL VEKTOR

(57) Abstract: The present invention relates to an improved assay and in particular to an improved assay that is capable of consistently measuring antibody titre, especially neutralising antibody (NAb) titre, at lower thresholds and/or with greater speed than conventionally-known assays. The invention further relates to use of such assays in combination with the provision of gene therapy and/or in combination with the provision of methods aimed at removal/depletion of neutralising antibodies from a patient.

WO 2021/152314 A1